Stock 002550 CHANGZHOU QIANHONG BIOPHARMA CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Changzhou Qianhong Biopharma CO.,LTD

Equities

002550

CNE100001070

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 29/05/2024 am IST 		5-day change 1st Jan Change
5.67 CNY -1.39% Intraday chart for Changzhou Qianhong Biopharma CO.,LTD -2.74% -3.57%
22/05 Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
26/04 Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD Stock Changzhou Qianhong Biopharma CO.,LTD
-3.57% 98Cr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.62% 73TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.34% 59TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.34% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.02% 32TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+0.39% 27TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 24TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
-6.63% 20TCr
A+
NOVARTIS AG Stock Novartis AG
+7.49% 20TCr
B-
AMGEN INC. Stock Amgen Inc.
+4.17% 16TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002550 Stock
  4. Ratings Changzhou Qianhong Biopharma CO.,LTD